Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Συνδρομές Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Ενδείξεις και αγωγές Βρείτε θεραπευτικές ενδείξεις και αγωγές για νόσους, συμπτώματα και ιατρικές πράξεις
Γνωρίζατε ότι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα

PARLODEL Capsule (2018)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

PARLODEL 5mg Capsules.

Qualitative and quantitative composition

Active substance: Ergotaman-3', 6', 18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl-5'-(2-methylpropyl)-, (5alpha)-mono-methanesulphonate. Each capsule contains 5.735mg of bromocriptine mesilate (equivalent ...

Pharmaceutical form

Light blue and white opaque hard gelatine capsules imprinted with 5 MG on the capsule body.

Therapeutic indications

Hyperprolactinaemia The treatment of hyperprolactinaemia in men and women with hypogonadism and/or galactorrhoea. Menstrual cycle disorders and female infertility Amenorrhoea and oligomenorrhoea, with ...

Posology and method of administration

PARLODEL should always be taken with food. A number of disparate conditions are amenable to treatment with PARLODEL and for this reason the recommended dosage regimens are variable. In most indications, ...

Contraindications

Hypersensitivity to bromocriptine or to any of the excipients of PARLODEL (see Section 2 Qualitative and Quantitative composition and Section 6.1 List of excipients) or to other ergot alkaloids. Bromocriptine ...

Special warnings and precautions for use

PARLODEL is contraindicated for use in the suppression of lactation or other non-life threatening indications in patients with severe coronary artery disease, or symptoms and/or a history of serious mental ...

Interaction with other medicinal products and other forms of interaction

Tolerance to PARLODEL may be reduced by alcohol. Caution is required in patients who are on concomitant therapy with, or have recently been treated with drugs that can alter blood pressure. Although there ...

Fertility, pregnancy and lactation

Pregnancy If pregnancy occurs it is generally advisable to withdraw PARLODEL after the first missed menstrual period. Rapid expansion of pituitary tumours sometimes occurs during pregnancy and this may ...

Effects on ability to drive and use machines

Hypotensive reactions may be disturbing in some patients during the first few days of treatment and particular care should be exercised when driving vehicles or operating machinery. Patients being treated ...

Undesirable effects

The occurrence of side-effects can be minimised by gradual introduction of the dose or a dose reduction followed by a more gradual titration. If necessary, initial nausea and/or vomiting may be reduced ...

Overdose

Signs and Symptoms Overdosage with PARLODEL is likely to result in vomiting and other symptoms which could be due to over stimulation of dopaminergic receptors and might include nausea, dizziness, hypotension, ...

Pharmacodynamic properties

Pharmacotherapeutic group: Dopamine agonist (ATC code: N04BC01) Prolactin inhibitor (ATC code: G02CB01) PARLODEL, active ingredient bromocriptine, is an inhibitor of prolactin secretion and a stimulator ...

Pharmacokinetic properties

Following oral administration, PARLODEL (bromocriptine) is rapidly and well absorbed. Peak plasma levels are reached within 1-3 hours. An oral dose of 5mg of bromocriptine results in a C<sub>max</sub> ...

Preclinical safety data

Pre-clinical data for PARLODEL (bromocriptine) reveal no special hazard for humans based on conventional studies of single and repeat dose toxicity, genotoxicity, mutagenicity, carcinogenic potential or ...

List of excipients

Capsule Content: Silica, colloidal anhydrous Magnesium stearate Maleic acid Maize starch Lactose monohydrate Capsule Shell: Indigo carmine (E132) Titanium dioxide (E171) Gelatin Printing Ink: Shellac (E904) ...

Incompatibilities

None.

Shelf life

<u>Opaque white PV/PVDC blister strip:</u> 24 months. <u>Amber glass bottle:</u> 36 months.

Special precautions for storage

<u>Amber glass bottle:</u> Store below 30°C. Store in the original package in order to protect from light. <u>Opaque white PV/PVDC blister strip:</u> Store below 25°C. Store in the original package in ...

Nature and contents of container

Opaque white PV/PVDC blister strip containing 30 PARLODEL 5mg capsules. Amber glass bottle with a tamper resistant closure containing 100 PARLODEL 5mg capsules. Not all pack sizes will be marketed.

Special precautions for disposal and other handling

No special requirements.

Marketing authorization holder

Mylan Products Ltd, Station Close, Potters Bar, Hertfordshire, EN6 1TL, United Kingdom

Marketing authorization number(s)

PL 46302/0138

Date of first authorization / renewal of the authorization

09 October 1981 / 27 October 1997

Date of revision of the text

27/02/2018

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:

Μπορείτε να υποστηρίξετε τον Γαληνό στην αποστολή του να παρέχει δωρεάν έγκυρη πληροφόρηση για κάθε φάρμακο απενεργοποιώντας το Ad Blocker για αυτόν τον ιστότοπο.